Anita Kumar

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Erin M. Bange, Nicholas Han, Paul Wileyto et al. · Nature Medicine · 2021 · 503 citations · Full text

Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response

Neil Steven, Nicola Annels, Anita Kumar et al. · The Journal of Experimental Medicine · 1997 · 349 citations · Full text

Ebv Disease Pathogenesis, Immunology, Pathology +18

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom et al. · The Lancet Oncology · 2015 · 263 citations

Lymphoid Neoplasia, Refractory Hodgkin, Augmented Ifosamide +10

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

Connie Lee Batlevi, Fushen Sha, Anna Alperovich et al. · Blood Cancer Journal · 2020 · 185 citations · Full text

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder et al. · Journal of Clinical Oncology · 2021 · 183 citations · Full text